ABBOTT ENTERS AGREEMENT WITH ADVANCED LIFE SCIENCE INSTITUTE

Abbott announced recently it has entered into a licensing agreement with Advanced Life Science Institute, Inc. (ALSI) for its Pro-gastrin-releasing peptide (ProGRP). ProGRP is a biomarker that may assist clinicians in diagnosing and monitoring small cell lung cancer, an aggressive type of cancer that can multiply quickly and rapidly spread throughout the body. Currently, no diagnostic test is approved in the U.S. for testing serum for lung cancer.
Financial News USA